AbbVie's SKYRIZI Wins EU Pediatric Psoriasis Approval, Bolstering Immunology Portfolio

What happened

The European Commission has approved SKYRIZI (risankizumab) for children and adolescents aged 6 and older with moderate to severe plaque psoriasis, based on the Phase 3 OptIMMize-1 and OptIMMize-2 trials. This expands SKYRIZI's label into a new patient population and introduces a 55 mg pre-filled syringe for weight-based dosing, potentially driving incremental volume growth. The approval is a positive but expected catalyst, consistent with AbbVie's strategy to extend SKYRIZI's lifecycle and support its $21.5 billion 2026 revenue target. However, the DeepValue master report stresses that AbbVie's thesis remains contingent on SKYRIZI and Rinvoq maintaining share capture in adult indications and meeting the 2026 immunology framework of $34.5 billion. This pediatric indication, while supportive, does not address the primary risks of payer access, pricing headwinds, or the need for aesthetics recovery, leaving the investment case unchanged.

Implication

Long-term, pediatric psoriasis adds a new demand source and potentially extends SKYRIZI's revenue durability. However, the core thesis still depends on adult share capture and the Rinvoq exclusivity runway. Without progress on pipeline diversification or aesthetics stabilization, the single-franchise concentration risk persists.

Thesis delta

This approval reinforces the base case of SKYRIZI volume-led growth but does not alter the wait-and-see stance. The key thesis breakers—Rinvoq's 2037 exclusivity, low-single-digit pricing headwinds, and aesthetics recovery—remain unresolved. No delta; the investment call stays at WAIT with a 3-6 month re-assessment window.